NHS delivers a further 5,000 permanent hospital beds
A total of 103,277 general and acute beds are now available to NHS patients
Read More
Tag: flu
UKHSA urges individuals from ethnic minority groups to get vaccinated
New data highlights the inequalities in emergency hospital rates and vaccinations
Read More
UKHSA launches campaign for flu and COVID-19 vaccines
The NHS has already delivered over 20 million winter vaccines this year
Read More
NIH clinical trial for universal influenza vaccine begins
The universal vaccine could protect people against more strains of flu
Read More
UK government invests £200m to boost NHS resilience this winter
The funding will reduce waiting lists and ease the demand on the NHS during Winter
Read More
First patient dosed in pivotal CureVac flu vaccine study
Modified influenza vaccine candidates have been developed in collaboration with GSK
Read More
3.2m UK birds culled as record avian flu cases increase
Virus can be lethal to humans and its spread is likely to accelerate this winter
Read More
Positive in vitro results for Imutex’s FLU-v
Data further supports the continued development of FLU-v as a broad-spectrum influenza vaccine
Read More
Quidel gains CE mark for combined COVID-19, flu and RSV diagnostic test
Company’s molecular testing platform and first assay panel can now be marketed in the EU
Read More
Xofluza effective as preventative flu medicine
Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise healthy patients.
Read More
Flu vaccine could reduce risk of death for elderly patients
For those who were vaccinated the risk of suffering a stroke was 16% lower than those who weren’t.
Read More
Approval for Seqirus flu vaccine
Seqirus has announced European approval of its new cell-based quadrivalent influenza vaccine.
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
